8-K filing — Erasca, Inc. (ERAS)
Filed: 2026-08-24 AccNo: 0001193125-26-361895 Size: 155 KB Item 8.01: Other Events
Stocks · News reference
Erasca Announces FDA Granted Fast Track Designation To ERAS-0015 For Metastatic Pancreatic Adenocarcinoma
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises the price target from $18 to $20.
Guggenheim Maintains Buy on Erasca, Raises Price Target to $21
Guggenheim analyst Paul Jeng maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $20 to $21.